Local 12, WCPO highlight brain tumor vaccine trial
Local television stations Local 12 and WCPO recently highlighted the Imvax trial that will test a personalized immunotherapy approach designed to work similarly to a vaccine by training the immune system to fight glioblastomas, a deadly brain tumor.
The University of Cincinnati is a study site for the new Phase 2b clinical trial, and Soma Sengupta, MD, PhD, is the site principal investigator.
In the trial, glioblastoma patients will have their tumors removed, and then their tumor cells will be combined with a novel drug to create a personalized vaccine. The combination is then inserted into the patients' abdomens, allowing the immune system to train to fight the tumor cells.
"The patient is making their own antibodies, and their own immune system is working to try and beat this cancer," Sengupta told Local 12.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
LastPass password manager now available for UC staff
May 17, 2024
The University of Cincinnati has partnered with LastPass to provide staff with enhanced password management services. This news article provides more details about the initiative launched on May 1, offering information and resources to help staff set up and use LastPass effectively for improved online security.
Can new rules in Ohio address a pharmacy staffing shortage and improve care?
May 17, 2024
The University of Cincinnati's Michael Hegener joined WVXU's Cincinnati Edition to discuss recent rules released by the Ohio Board of Pharmacy designed to address pharmacy staffing.
UC’s Dean Lawrence J. Johnson, a transformative figure in CECH, celebrates 25 years
May 17, 2024
The University of Cincinnati's College of Education, Criminal Justice, Human Services, and Information Technology Dean Lawrence J. Johnson retires this year after 25 years in the role (and 34 years with the college). In this article we look at his road to academia and journey to a transformative quarter century at UC.